This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Clover Biopharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Clover Biopharmaceuticals te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

190.4%

Groei van de winst per aandeel

Biotechs winstgroei	41.1%
Inkomstengroei	47.9%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	27 Jul 2023

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

SZSC:2197 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	2,341	N/A	N/A	N/A	1
12/31/2024	3,071	N/A	N/A	N/A	2
12/31/2023	2,571	N/A	N/A	N/A	2
6/30/2023	0	-665	N/A	N/A	N/A
3/31/2023	0	-1,559	N/A	N/A	N/A
12/31/2022	N/A	-2,452	-1,796	-1,691	N/A
9/30/2022	N/A	-4,145	-1,461	-1,356	N/A
6/30/2022	N/A	-5,838	-1,125	-1,021	N/A
3/31/2022	N/A	-5,927	-1,062	-969	N/A
12/31/2021	N/A	-6,016	-998	-918	N/A
12/31/2020	N/A	-913	363	477	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van 2197 boven de spaarquote ( 1.9% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van 2197 naar verwachting sneller zal groeien dan de markt Hong Kong

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van 2197 naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: De omzet van 2197 ( 47.9% per jaar) zal naar verwachting sneller groeien dan de markt Hong Kong ( 7.7% per jaar).

Hoge groei-inkomsten: De omzet van 2197 ( 47.9% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van 2197 naar verwachting over 3 jaar hoog zal zijn

This company listing is no longer active

Clover Biopharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Founder recently bought HK$1.2m worth of stock

CEO & Executive Director recently bought HK$595k worth of stock

New major risk - Financial position

Clover Biopharmaceuticals, Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Clover Biopharmaceuticals, Ltd. Provides Updates on Business and R&D Pipeline Development

Clover Biopharmaceuticals, Ltd. announced that it has received $48.882447 million in funding

Clover Launches Covid-19 Booster Vaccine in the People’s Republic of China

Clover Biopharmaceuticals, Ltd. Provides Updates on COVID-19 Vaccine Commercial Launch

Founder recently bought HK$1.0m worth of stock

Clover Biopharmaceuticals, Ltd. Announces COVID-19 Vaccine, SCB-2019 (CpG 1018/ Alum), Has Been Evaluated by Relevant Authorities of the People's Republic of China and Included for Emergency Use in the PRC

Clover Biopharmaceuticals, Ltd. Announces Vaccine Candidate Reduced Household Transmission of SARS-COV-2 by 84% in Study Published in Clinical Infectious Diseases

Less than half of directors are independent

Clover Biopharmaceuticals, Ltd. Announces Board Changes

Founder recently bought HK$636k worth of stock

Founder recently bought HK$421k worth of stock

Founder recently bought HK$1.2m worth of stock

Clover Biopharmaceuticals, Ltd.'s COVID-19 Vaccine Candidate Receives European Union GMP Certificate

Clover Biopharmaceuticals, Ltd. Announces Positive Data from Its Ongoing Phase 3 Study Evaluating IT’S SCB-2019

Clover Biopharmaceuticals, Ltd. Announces Covid-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine

Clover Biopharmaceuticals, Ltd. Announces Covid-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine

Clover Biopharmaceuticals, Ltd.’s COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5

Clover Announces Positive Phase 2/3 Results in Adolescents for Its Covid-19 Vaccine

Clover Biopharmaceuticals, Ltd. to Report First Half, 2022 Results on Aug 23, 2022

Clover Biopharmaceuticals, Ltd. Announces Executive Changes

Clover Biopharmaceuticals, Ltd. Announces New Positive Clinical Data in Individuals Vaccinated with A Third Dose of Scb-2019 as A Homologous Booster Against the Omicron Variant

Clover Biopharmaceuticals, Ltd. Appoints Donna Ambrosino, M.D., and Ralf Clemens, M.D., Ph.D., to Board of Directors

Clover Biopharmaceuticals, Ltd. Doses First Patient with Scb-219M in Phase 1 Trial for Chemotherapy-Induced Thrombocytopenia

Clover Biopharmaceuticals, Ltd. Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector Vaccines

Clover Biopharmaceuticals, Ltd. Doses First Participants in Phase 1 Trial with SCB-2020S, Potentially Broadly Protective Chimeric COVID-19 Vaccine Candidate

Less than half of directors are independent

Clover Biopharmaceuticals, Ltd. Announces Board Changes

Clover Biopharmaceuticals, Ltd., Annual General Meeting, May 27, 2022

High number of new and inexperienced directors

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven